Roche and BioNTech stole the show at this year’s San Antonio Breast Cancer Symposium. The Swiss drugmaker unveiled Phase 3 data for its oral SERD

Another TIGIT program has failed in the clinic, this time in a Phase 3 study. Arcus and Gilead said on Friday that their anti-TIGIT antibody

Plus, news about BioCryst, Cycle Pharma, Applied Therapeutics, Contineum Therapeutics, Juncell Therapeutics, Cosette and Mayne Pharma: 📊 Innovent’s mazdutide shows early promise in adolescents: The

GSK has offloaded a corporate venture unit that invests in bioelectronic startups working on neuromodulation, wearables, implanted devices and other technology, Endpoints News has learned.

Tenaya Therapeutics, a company focused on developing gene therapies for heart conditions, made a series of announcements on Thursday. The biotech said the FDA has